Market Research Logo

A Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, Ischemia-modified Albumin, and Others)

Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, Ischemia-modified Albumin, and Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others) and Location of Testing (Point of care Testing and Laboratory Testing): Global Opportunity Analysis and Industry Forecast, 2019–2026

The global cardiac biomarker market generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4%. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state as well as for diagnostic and prognostic purposes associated with heart. The prevention of cardiac diseases by monitoring heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS), and others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA, and others. The global cardiac biomarkers testing market has witnessed a greater demand over the past five to six years.

The ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain acts as a key factor that boosts the growth of the global cardiac market. In addition, promising features such as high accuracy, quick outcomes, and economic pricing of cardiac point of care (POC) testing drive the market growth. To keep the momentum of cardiac marker tests, key manufacturers offer customized solutions, thus propelling the growth of the market. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions serves as the key opportunity for market expansion. However, limited specificity in some cases and side effects such as skeletal muscle injury restrain the growth of the cardiac biomarkers testing market.

The global cardiac biomarker market is segmented based on type, application, location of testing, and region. By type, the market is fragmented into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and others. Depending on application, it is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, it is bifurcated into point of care testing and laboratory testing. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report highlights the market dynamics to understand the global cardiac biomarker market and capitalize on the prevailing opportunities.
Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.

KEY MARKET SEGMENTS

By Type

Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others

By Application

Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others

By Location of Testing

Point of Care Testing
Laboratory Testing

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
Spain
Italy
UK
Rest of Europe
Asia-Pacific
Australia
Japan
India
China
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa

KEY MARKET PLAYERS

Roche Diagnostics
Abbott Laboratories
Siemens Healthcare
Becton, Dickinson and Company
Bio-Rad Laboratories
BioMerieux
PerkinElmer Inc.
Tosoh Corporation
Danaher Corporation
Thermo Fisher Scientific

The other players in the value chain include (profiles not included in the report):

Randox Laboratories
Johnson and Johnson
Olympus Corporation
BG Medicines
ACS Biomarker B.V.
Cavadis Biomedical.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings
2.1.1. Top impacting factors
2.1.2. Top investment pockets
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Biomarker diagnosis vs. conventional diagnosis
3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers
3.3.1. Early diagnosis
3.3.2. Tissue specific diagnosis
3.3.3. Reduce clinical trials
3.3.4. Consistent output
3.4. Key trends impacting the Cardiac biomarker testing market
3.4.1. Development of high sensitive biomarkers for risk stratification
3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3. Increasing demand for point of care cardiac diagnostics
3.5. Parent Market Overview
3.6. Key Forces Shaping Cardiac biomarker testing market
3.6.1. High bargaining power of suppliers
3.6.2. Low bargaining power of buyers
3.6.3. Low threat of new entrants
3.6.4. Low threat of substitutes
3.6.5. High intensity of rivalry
3.7. Value chain analysis
3.8. Pricing Analysis
3.8.1. Pricing Analysis, By Region, 2018 & 2025
3.9. Market evolution/Industry roadmap
3.10. Government regulations
3.11. Reimbursement issues
3.12. Patent Analysis
3.12.1. By Region (2016-2018)
3.12.2. By Applicant
3.13. Market share analysis
3.14. Case Studies
3.14.1. Case Study
3.15. Market dynamics
3.15.1. Drivers
3.15.1.1. Increasing prevalence of cardiovascular diseases
3.15.1.2. Cost effective
3.15.1.3. Non-invasive
3.15.1.4. Accuracy prediction
3.15.1.5. Technological advancements using cardiac biomarkers combinations
3.15.1.6. Increasing point of care (POC) testing
3.15.2. Restraints
3.15.2.1. Government Regulation
3.15.2.2. Conformation in result
3.15.2.3. Complex process
3.15.3. Opportunities
3.15.3.1. Personalized medicine
3.15.3.2. Point of care (POCT) testing using cardiac biomarkers
CHAPTER 4: CARDIAC BIOMARKER TESTING MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Creatine kinase (CK-MB)
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Troponins
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Myoglobin
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Natriuretic peptides (BNP and NT-proBNP)
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Ischemia modified albumin
4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
CHAPTER 5: CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Myocardial infarction
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Congestive heart failure
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Acute coronary syndrome
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Atherosclerosis
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other applications
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING
6.1. Overview
6.1.1. Market size and forecast
6.2. Point of care testing
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Laboratory testing
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
CHAPTER 7: CARDIAC BIOMARKER TESTING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. North America market size and forecast, by type
7.2.3. North America market size and forecast, by application
7.2.4. North America market size and forecast, by location of testing
7.2.5. North America market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. U.S. market size and forecast, by type
7.2.5.1.2. U.S. market size and forecast, by application
7.2.5.1.3. U.S. market size and forecast, by location of testing
7.2.5.2. Canada
7.2.5.2.1. Canada market size and forecast, by type
7.2.5.2.2. Canada market size and forecast, by application
7.2.5.2.3. Canada market size and forecast, by location of testing
7.2.5.3. Mexico
7.2.5.3.1. Mexico market size and forecast, by type
7.2.5.3.2. Mexico market size and forecast, by application
7.2.5.3.3. Mexico market size and forecast, by location of testing
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Europe market size and forecast, by type
7.3.3. Europe market size and forecast, by application
7.3.4. Europe market size and forecast, by location of testing
7.3.5. Europe market size and forecast, by country
7.3.5.1. UK
7.3.5.1.1. UK market size and forecast, by type
7.3.5.1.2. UK market size and forecast, by application
7.3.5.1.3. UK market size and forecast, by location of testing
7.3.5.2. France
7.3.5.2.1. France market size and forecast, by type
7.3.5.2.2. France market size and forecast, by application
7.3.5.2.3. France market size and forecast, by location of testing
7.3.5.3. Germany
7.3.5.3.1. Germany market size and forecast, by type
7.3.5.3.2. Germany market size and forecast, by application
7.3.5.3.3. Germany market size and forecast, by location of testing
7.3.5.4. Rest of Europe
7.3.5.4.1. Rest of Europe market size and forecast, by type
7.3.5.4.2. Rest of Europe market size and forecast, by application
7.3.5.4.3. Rest of Europe market size and forecast, by location of testing
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by type
7.4.3. Asia-Pacific market size and forecast, by application
7.4.4. Asia-Pacific market size and forecast, by location of testing
7.4.5. Asia-Pacific market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. China market size and forecast, by type
7.4.5.1.2. China market size and forecast, by application
7.4.5.1.3. China market size and forecast, by location of testing
7.4.5.2. India
7.4.5.2.1. India market size and forecast, by type
7.4.5.2.2. India market size and forecast, by application
7.4.5.2.3. India market size and forecast, by location of testing
7.4.5.3. Australia
7.4.5.3.1. Australia market size and forecast, by type
7.4.5.3.2. Australia market size and forecast, by application
7.4.5.3.3. Australia market size and forecast, by location of testing
7.4.5.4. Japan
7.4.5.4.1. Japan market size and forecast, by type
7.4.5.4.2. Japan market size and forecast, by application
7.4.5.4.3. Japan market size and forecast, by location of testing
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Rest of Asia-Pacific market size and forecast, by type
7.4.5.5.2. Rest of Asia-Pacific market size and forecast, by application
7.4.5.5.3. Rest of Asia-Pacific market size and forecast, by location of testing
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. LAMEA market size and forecast, by type
7.5.3. LAMEA market size and forecast, by application
7.5.4. LAMEA market size and forecast, by location of testing
7.5.5. LAMEA market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Latin America market size and forecast, by type
7.5.5.1.2. Latin America market size and forecast, by application
7.5.5.1.3. Latin America market size and forecast, by location of testing
7.5.5.2. Middle East
7.5.5.2.1. Middle East market size and forecast, by type
7.5.5.2.2. Middle East market size and forecast, by application
7.5.5.2.3. Middle East market size and forecast, by location of testing
7.5.5.3. Africa
7.5.5.3.1. Africa market size and forecast, by type
7.5.5.3.2. Africa market size and forecast, by application
7.5.5.3.3. Africa market size and forecast, by location of testing
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Becton, Dickinson and Company
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BioMerieux
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.4. Bio-Rad Laboratories, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. Danaher Corporation
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. F. HOFFMANN-LA ROCHE LTD.
2
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.7. Siemens AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. Thermo Fisher Scientific, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.9. PerkinElmer Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.10. Tosoh Corporation
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
LIST OF TABLES
TABLE 01. CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 02. CASE STUDY
TABLE 03. APPLICATIONS AND BENEFITS OF POINT OF CARE TESTING
TABLE 04. CARDIAC BIOMARKERS FOR CVD IN TNT
TABLE 05. CHARACTERISTICS OF CARDIAC BIOMARKER
TABLE 06. GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07. CARDIAC BIOMARKER TESTING MARKET FOR CREATINE KINASE, BY REGION, 2018–2026 ($MILLION)
TABLE 08. CARDIAC BIOMARKER TESTING MARKET FOR ARTHROSPIRA MAXIMA, BY REGION, 2018–2026 ($MILLION)
TABLE 09. CARDIAC BIOMARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2018–2026 ($MILLION)
TABLE 10. CARDIAC BIOMARKER TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), BY REGION, 2018–2026 ($MILLION)
TABLE 11. CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN, BY REGION, 2018–2026 ($MILLION)
TABLE 12. CARDIAC BIOMARKER TESTING MARKET FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 13. GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 14. CARDIAC BIOMARKERS USED FOR MONITORING PATIENTS WITH MYOCARDIAL INFRACTIONS
TABLE 15. CARDIAC BIOMARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2018–2026, ($MILLION)
TABLE 16. CARDIAC BIOMARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2018–2026, ($MILLION)
TABLE 17. CARDIAC BIOMARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2018–2026, ($MILLION)
TABLE 18. CARDIAC BIOMARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2018–2026, ($MILLION)
TABLE 19. CARDIAC BIOMARKER TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2026, ($MILLION)
TABLE 20. GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 21. CARDIAC BIOMARKER TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2018–2026, ($MILLION)
TABLE 22. CARDIAC BIOMARKER TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2018–2026, ($MILLION)
TABLE 23. CARDIAC BIOMARKER TESTING MARKET, BY REGION, 2018–2026, ($MILLION)
TABLE 24. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 25. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 26. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 27. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 28. U.S. CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 29. U.S. CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 30. U.S. CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 31. CANADA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 32. CANADA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 33. CANADA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 34. MEXICO CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 35. MEXICO CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 36. MEXICO CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 37. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 38. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 39. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 40. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 41. UK CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 42. UK CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 43. UK CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 44. FRANCE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 45. FRANCE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 46. FRANCE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 47. GERMANY CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 48. GERMANY CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 49. GERMANY CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 50. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 51. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 52. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 53. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 54. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 55. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 56. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 57. CHINA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 58. CHINA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 59. CHINA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 60. INDIA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 61. INDIA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 62. INDIA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 63. AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 64. AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 65. AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 66. JAPAN CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 67. JAPAN CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 68. JAPAN CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 72. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 73. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 74. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 75. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 76. LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 77. LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 78. LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 79. MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 80. MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 81. MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 82. AFRICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018–2026, ($MILLION)
TABLE 83. AFRICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018–2026, ($MILLION)
TABLE 84. AFRICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018–2026, ($MILLION)
TABLE 85. ABBOTT: COMPANY SNAPSHOT
TABLE 86. ABBOTT: OPERATING SEGMENTS
TABLE 87. ABBOTT: PRODUCT PORTFOLIO
TABLE 88. BD: COMPANY SNAPSHOT
TABLE 89. BD: OPERATING SEGMENTS
TABLE 90. BD: PRODUCT PORTFOLIO
TABLE 91. BIOMÉRIEUX, INC.: COMPANY SNAPSHOT
TABLE 92. BIOMÉRIEUX, INC.: OPERATING SEGMENTS
TABLE 93. BIO-RAD: COMPANY SNAPSHOT
TABLE 94. BIO-RAD: OPERATING SEGMENTS
TABLE 95. DANAHER: COMPANY SNAPSHOT
TABLE 96. DANAHER: OPERATING SEGMENTS
TABLE 97. ROCHE: COMPANY SNAPSHOT
TABLE 98. ROCHE: OPERATING SEGMENTS
TABLE 99. SEIMENS: COMPANY SNAPSHOT
TABLE 100. SEIMENS: PRODUCT SEGMENTS
TABLE 101. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 102. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 103. PERKINELMER: COMPANY SNAPSHOT
TABLE 104. PERKINELMER: OPERATING SEGMENTS
TABLE 105. TOSOH: COMPANY SNAPSHOT
TABLE 106. TOSOH: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 01. TOP IMPACTING FACTORS, 2018-2026
FIGURE 02. TOP INVESTMENT POCKETS, 2018
FIGURE 03. PARENT MARKET
FIGURE 04. VALUE CHAIN ANALYSIS OF GLOBAL CARDIAC BIOMARKERS
FIGURE 05. PRICING ANALYSIS, BY REGION, 2018 & 2025
FIGURE 06. PATENT ANALYSIS, BY REGION
FIGURE 07. PATENT ANALYSIS, BY APPLICANT
FIGURE 08. MARKET SHARE ANALYSIS, 2018
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR CREATINE KINASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ARTHROSPIRA MAXIMA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR NUTRACEUTICALS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR POINT OF CARE TESTING, BY COUNTRY, 2018 & 2026 (%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR LABORATORY TESTING, BY COUNTRY, 2018 & 2026 (%)
FIGURE 22. ABBOTT: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 25. BD: NET SALES, 2015–2017 ($MILLION)
FIGURE 26. BD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. BD: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 28. BIOMÉRIEUX, INC.: REVENUE, 2015–2017 ($MILLION)
FIGURE 29. BIOMÉRIEUX, INC.: REVENUE SHARE BY APPLICATION, 2017 (%)
FIGURE 30. BIOMÉRIEUX, INC.: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. BIO-RAD: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33. BIO-RAD: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 34. DANAHER: NET SALES, 2016–2018 ($MILLION)
FIGURE 35. DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36. DANAHER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 37. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. SEIMENS: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. SEIMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)
FIGURE 42. SEIMENS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 43. THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 44. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 46. PERKINELMER: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48. PERKINELMER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 49. TOSOH: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. TOSOH: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51. TOSOH: REVENUE SHARE BY REGION, 2018 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report